Organogenesis Holdings (ORGO) Current Deferred Revenue (2025)
Organogenesis Holdings' (ORGO) quarterly Current Deferred Revenue came in at $3.9 million in Q4 2025, up 31.06% quarter-over-quarter from $2.9 million in Q3 2025.
Organogenesis Holdings (ORGO) Current Deferred Revenue (2025) Analysis & Trends
Organogenesis Holdings' Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $3.9 million for Q4 2025.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $3.9 million in Q4 2025; TTM through Dec 2025 was $3.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.9 million, changed N/A from the prior year.
- Current Deferred Revenue grew to $3.9 million in Q4 2025 per ORGO's latest filing, from $2.9 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $3.9 million in Q4 2025 and bottomed at $2.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Organogenesis Holdings | 310.55 Mn | 218.45 Mn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.86 Mn |
| Sep 30, 2025 | 2.95 Mn |
| Jun 30, 2025 | 2.68 Mn |